FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3

Endocrine-Related Cancer

Volumn 20, Issue 3, 2013, Pages 415-429

  Tao, Xiang ^a   Zhao, Naiqing ^a   Jin, Hongyan ^a   Zhang, Zhenbo ^d   Liu, Yintao ^a   Wu, Jian ^b   Bast, Robert C ^c   Yu, Yinhua ^a   Feng, Youji ^a,d  

^a FUDAN UNIVERSITY   (China)

^b Gongli Hospital   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Cell proliferation; Follicle stimulating hormone (FSH); Ovarian epithelial cancer; Prognosis; Transient receptor potential channel C3 (TRPC3)

Indexed keywords

FOLLITROPIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PROTEIN KINASE B; SMALL INTERFERING RNA; SURVIVIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL 3; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CALCIUM TRANSPORT; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CORRELATION ANALYSIS; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; OVARY CANCER; OVERALL SURVIVAL; POSTMENOPAUSE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; UPREGULATION;

EID: 84879488845     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0005     Document Type: Article

References (44)

1. Abramowitz J & Birnbaumer L 2009 Physiology and pathophysiology of canonical transient receptor potential channels. FASEB Journal 23 297-328. (doi:10.1096/fj.08-119495)
2. Arslan AA, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Lukanova A, Afanasyeva Y, Lenner P, Krogh V, Muti P, Rinaldi S et al. 2003 Serum follicle-stimulating hormone and risk of epithelial ovarian cancer in postmenopausal women. Cancer Epidemiology, Biomarkers & Prevention 12 1531-1535.
3. Berek JS & Natarajan S 2007 Ovarian and fallopian tube cancer. In Berek & Novak's Gynecology, pp 1458-1547. Ed JS Berek., 14th edn Philadelphia: Lippincott Williams & Wilkins.
4. Biskind M & Biskind G 1944 Development of tumors in the rat ovary after transplantation into the spleen. Proceedings of the Society for Experimental Biology and Medicine 55 176-179.
5. Cai R, Ding X, Zhou K, Shi Y, Ge R, Ren G, Jin Y & Wang Y 2009 Blockade of TRPC6 channels induced G2/M phase arrest and suppressed growth in human gastric cancer cells. International Journal of Cancer 125 2281-2287. (doi:10.1002/ijc.24551)
6. Chakravarti S, Collins WP, Forecast JD, Newton JR, Oram DH & Studd JW 1976 Hormonal profiles after the menopause. BMJ 2 784-787. (doi:10.1136/bmj.2. 6039.784)
7. Chen FC, Oskay-Ozcelik G, Buhling KJ, Kopstein U, Mentze M, Lichtenegger W & Sehouli J 2009 Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer. Anticancer Research 29 1575-1578.
8. Cheng ZP, Tao X, Gong J, Dai H, Hu LP & Yang WH 2009 Early-stage morphological observations of myoma and myometrium after laparoscopic uterine artery occlusion treatment. European Journal of Obstetrics, Gynecology, and Reproductive Biology 145 113-116. (doi:10.1016/j.ejogrb.2009.03.027)
9. Chigurupati S, Venkataraman R, Barrera D, Naganathan A, Madan M, Paul L, Pattisapu JV, Kyriazis GA, Sugaya K, Bushnev S et al. 2010 Receptor channel TRPC6 is a key mediator of Notch-driven glioblastoma growth and invasiveness. Cancer Research 70 418-427. (doi:10.1158/0008-5472.CAN-09-2654)
10. Choi JH, Choi KC, Auersperg N & Leung PC 2005 Gonadotropins upregulate the epidermal growth factor receptor through activation of mitogen-activated protein kinases and phosphatidyl-inositol-3-kinase in human ovarian surface epithelial cells. Endocrine-Related Cancer 12 407-421. (doi:10.1677/erc.1.00896)
11. Choi JH, Choi KC, Auersperg N & Leung PC 2006 Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Research 66 3912-3920. (doi:10.1158/0008-5472. CAN-05-1785)
12. Choi JH, Wong AS, Huang HF & Leung PC 2007 Gonadotropins and ovarian cancer. Endocrine Reviews 28 440-461. (doi:10.1210/er.2006-0036)
13. 2+/CaM in the activation of MAPK and p38γ. Advances in Experimental Medicine and Biology 475 293-302.
14. Cramer DW & Welch WR 1983 Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. Journal of the National Cancer Institute 71 717-721.
15. Ding X, He Z, Zhou K, Cheng J, Yao H, Lu D, Cai R, Jin Y, Dong B, Xu Y et al. 2010 Essential role of TRPC6 channels in G2/M phase transition and development of human glioma. Journal of the National Cancer Institute 102 1052-1068. (doi:10.1093/jnci/djq217)
16. El Hiani Y, Ahidouch A, Lehen'kyi V, Hague F, Gouilleux F, Mentaverri R, Kamel S, Lassoued K, Brule G & Ouadid-Ahidouch H 2009 Extracellular signal-regulated kinases 1 and 2 and TRPC1 channels are required for calcium-sensing receptor-stimulated MCF-7 breast cancer cell proliferation. Cellular Physiology and Biochemistry 23 335-346. (doi:10. 1159/000218179)
17. Feldman B, Fedida-Metula S, Nita J, Sekler I & Fishman D 2010 Coupling of mitochondria to store-operated Ca(2C)-signaling sustains constitutive activation of protein kinase B/Akt and augments survival ofmalignant melanomacells. Cell Calcium 47525-537. (doi:10.1016/j.ceca.2010.05. 002)
18. Flockerzi V 2007 An introduction on TRP channels. In Handbook of Experimental Pharmacology: Transient Receptor Potential (TRP) Channels, pp 1-19. Eds V Flockerzi & B Nilius. Berlin/Heidelberg, Germany: Springer (doi:10.1007/978-3-540-34891-7-1)
19. Franceschi S, La Vecchia C, Booth M, Tzonou A, Negri E, Parazzini F, Trichopoulos D & Beral V 1991 Pooled analysis of three European case-control studies of epithelial ovarian cancer: II. Age at menarche and menopause. International Journal of Cancer 49 57-60. (doi:10.1002/ijc.2910490111)
20. Goel M, Zuo CD & Schilling WP 2010 Role of cAMP/PKA signaling cascade in vasopressin-induced trafficking of TRPC3 channels in principal cells of the collecting duct. American Journal of Physiology. Renal Physiology 298 F988-F996. (doi:10.1152/ajprenal.00586.2009)
21. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, et al. 2011 Cancer of the ovary. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute (http://seer.cancer.gov/csr/1975-2008/, based on November 2010 SEER data submission).
22. Hu YL, Tee MK, Goetzl EJ, Auersperg N, Mills GB, Ferrara N & Jaffe RB 2001 Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. Journal of the National Cancer Institute 93 762-768. (doi:10.1093/jnci/93.10.762)
23. Huang Y, Hua K, Zhou X, Jin H, Chen X, Lu X, Yu Y, Zha X & Feng Y 2008 Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. Cell Research 18 780-791. (doi:10.1038/cr.2008.70)
24. Huang Y, Jin H, Liu Y, Zhou J, Ding J, Cheng KW, Yu Y & Feng Y 2011 FSH inhibits ovarian cancer cell apoptosis by up-regulating survivin and down-regulating PDCD6 and DR5. Endocrine-Related Cancer 18 13-26. (doi:10.1677/ERC-09-0308)
25. Kanzaki M, Zhang YQ, Mashima H, Li L, Shibata H & Kojima I 1999 Translocation of a calcium-permeable cation channel induced by insulin-like growth factor-I. Nature Cell Biology 1 165-170. (doi:10.1038/11086)
26. Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R et al. 2006 Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biology & Therapy 5 1708-1713. (doi:10.4161/cbt.5.12.3468)
27. Lanner JT, Bruton JD, Assefaw-Redda Y, Andronache Z, Zhang SJ, Severa D, Zhang ZB, Melzer W, Zhang SL, Katz A et al. 2009 Knockdown of TRPC3 with siRNA coupled to carbon nanotubes results in decreased insulinmediated glucose uptake in adult skeletal muscle cells. FASEB Journal 23 1728-1738. (doi:10.1096/fj.08- 116814)
28. Lau MT, Wong AS & Leung PC 2010 Gonadotropins induce tumor cell migration and invasion by increasing cyclooxygenases expression and prostaglandin E(2) production in human ovarian cancer cells. Endocrinology 151 2985-2993. (doi:10.1210/en.2009-1318)
29. Mangala LS, Han HD, Lopez-Berestein G & Sood AK 2009 Liposomal siRNA for ovarian cancer. Methods in Molecular Biology 555 29-42. (doi:10.1007/978-1- 60327-295-7-3)
30. McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, Kaaks R, Rinaldi S & Helzlsouer KJ 2009 Prediagnostic circulating follicle stimulating hormone concentrations and ovarian cancer risk. International Journal of Cancer 125 674-679. (doi:10.1002/ijc.24406)
31. Mertens-Walker I, Bolitho C, Baxter RC & Marsh DJ 2010 Gonadotropininduced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C{δ}. Endocrine-Related Cancer 17 335-349. (doi:10.1677/ERC-09-0152)
32. Mikkelsen T, Lush R, Grossman SA, Carson KA, Fisher JD, Alavi JB & Rosenfeld S 2007 Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. Investigational New Drugs 25 259-263. (doi:10.1007/s10637-006-9023- 6)
33. 2+ transport. Nature Reviews. Cancer 7 519-530. (doi:10.1038/nrc2171)
34. Montell C 2005 The TRP superfamily of cation channels. Science's STKE 272 re3. (doi:10.1126/stke.2722005re3)
35. Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G et al. 2009 Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS ONE 4 e5583. (doi:10.1371/journal.pone. 0005583)
36. Park YH, Kim SJ, Jeong BH, Herzog TJ, Wright J, Kitajewski J, Rhim CC, Jang PR & Kang JB 2010 Follicular stimulating hormone enhances Notch 1 expression in SK-OV-3 ovarian cancer cells. Journal of Gynecologic Oncology 21 119-124. (doi:10.3802/jgo.2010.21.2.119)
37. Shimoyamada H, Yazawa T, Sato H, Okudela K, Ishii J, Sakaeda M, Kashiwagi K, Suzuki T, Mitsui H, Woo T et al. 2010 Early growth response-1 induces and enhances vascular endothelial growth factor-α expression in lung cancer cells. American Journal of Pathology 177 70-83. (doi:10.2353/ajpath.2010.091164)
38. Smyth JT, Lemonnier L, Vazquez G, Bird GS & Putney JW, Jr 2006 Dissociation of regulated trafficking of TRPC3 channels to the plasma membrane from their activation by phospholipase C. Journal of Biological Chemistry 281 11712-11720. (doi:10.1074/jbc.M510541200)
39. Sun L, Sakurai S, Sano T, Hironaka M, Kawashima O & Nakajima T 2009 High-grade neuroendocrine carcinoma of the lung: comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinoma. Pathology International 59 522-529. (doi:10.1111/j.1440-1827.2009.02402.x)
40. 2+ entry and proliferation of prostate cancer epithelial cells. Cancer Research 66 2038-2047. (doi:10.1158/0008-5472.CAN-05-0376)
41. Thomas CM, Boss EA, Boonstra H, van Tienoven D, Sweep CG & Massuger LF 2008 Gonadotropins and female sex steroid hormones in cyst fluid and serum from patients with ovarian tumors. European Journal of Gynaecological Oncology 29 468-472.
42. Vanderhyden BC 2005 Loss of ovarian function and the risk of ovarian cancer. Cell and Tissue Research 322 117-124. (doi:10.1007/s00441-005-1100-1)
43. Yang SL, Cao Q, Zhou KC, Feng YJ & Wang YZ 2009 Transient receptor potential channel C3 contributes to the progression of human ovarian cancer. Oncogene 28 1320-1328. (doi:10.1038/onc. 2008.475)
44. Zou CF, Jia L, Jin H, Yao M, Zhao N, Huan J, Lu Z, Bast RC, Jr, Feng Y & Yu Y 2011 Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel. BMC Cancer 11 22. (doi:10.1186/1471-2407-11-22)